Wegovy HD Approval: A Game Changer in Obesity T...

By João L. Carapinha

March 20, 2026

Novo Nordisk announced the Wegovy HD approval by the US Food and Drug Administration (FDA) for Wegovy® HD (semaglutide injection 7.2 mg), a higher-dose formulation showing superior weight loss over the existing 2.4 mg dose in adults with obesity. ...
Milestone Approval of Invasive Brain-Computer Interface Revolutionizes Spinal...
Accelerating Patient Access: MHRA NICE Alignment Initiative
Long-Term HPV Vaccine Effectiveness: Sustained Protection Against Cervical Di...
TAVI Reimbursement Expansion for Low- and Intermediate-Risk Patients: A New E...
PRIME Scheme Evaluation: Insights from Enhanced Development Tools Pilot
EU Approves Imfinzi Gastric Cancer Treatment as Perioperative Immunotherapy
Europe Life Sciences Competitiveness: Addressing Decline and Unlocking Potential
Bridging Analyses: The Role of Cost Per Event Avoided in Evaluating GLP-1 Ago...
EU Medicines Regulation Achievements: EMA’s 2025 Highlights and Future ...
Quantifying Cancer Productivity Losses in Europe: Economic Impact Analysis
Biomarin Withdraws Voxzogo Reimbursement Application in the Netherlands
Catalyzing Cardiovascular Health Innovation through Urban Interventions and C...